The company plans to publish 10 "gold standard" trials on its ingredients in the coming year.
Natreon (New Brunswick, NJ) has plans to publish more than 10 “gold standard” human trials on its ingredients in the upcoming year. When it’s all said and done, the published studies will be the culmination of more than $1 million invested in clinical research to keep up with growing demands from dietary supplement manufacturers.
The trials focus on Natreon’s branded ingredients, which are Sensoril ashwagandha, Capros amla fruit, Crominex3+ chromium complex, and PrimaVia shilajit-a blackish brown powder from high-mountain rocks. Findings reportedly span a wide range of health conditions, including stress relief, blood sugar control, heart health, energy, and sports performance. While the first study will likely publish before the end of this year, the others won’t be released until 2014. But the wait should be worth it. Natreon says it has shared findings with some nutritional product manufacturers and is planning to announce an exclusive supply agreement with a dietary supplement manufacturer before the end of this year.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
PEA may support exercise performance in addition to its anti-inflammatory properties
June 26th 2024The branded palmitoylethanolamide (PEA) ingredient called Levagen+ significantly improved dynamic lower body power, and did not inhibit strength training adaptations unlike NSAIDs or other analgesics.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.